3Q FY26 Quarterly Activity Report and Appendix 4C
Filed with ASX · · 9 pages · English
Summary by 6ix AI
The report highlights a decline in operating revenue and gross profit compared to the same period last year, attributed to lower customer renewal rates and budget pressures in the pharmaceutical sector. The company has made progress on its short-term priorities, including technology platform upgrades and cost reduction initiatives, aiming for cash flow break-even in the next quarter.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Watch Adheris Health's latest callMedAdvisor Limited (MDR) Q1 2026 Earnings Call · Replay · Oct 21, 2025Read the transcript of MedAdvisor Limited (MDR) Q1 2026 Earnings CallIn the deck
Story so far
Earlier from Adheris Health
- FY26 Half Year Results
- Appendix 4D & FY26 Half Year Report
- Non-Deal Roadshow Presentation & Operating Cost Update
- 2Q FY26 Quarterly Activity Report and Appendix 4C
- A$6.1m Holdback Consideration received
Later from Adheris Health
- Q3 FY26 Results Presentation
- 4Q FY26 Quarterly Activity Report and Appendix 4C
- Adheris Health legal claim
- Adheris FY26 Results
- 1Q FY27 Quarterly Activity Report and Appendix 4C
Follow Adheris Health into a list and get an email when it puts out news.
Follow Adheris Health